Clinical Comparative Study of Sulbactam/Ampicillin and Imipenem/Cilastatin in Elderly Patients with Community-Acquired Pneumonia

Katsunori Yanagihara; Yuichi Fukuda; Masafumi Seki; Koichi Izumikawa; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Kazuhiro Tsukamoto; Shigeru Kohno

doi:10.2169/internalmedicine.45.1717

ORIGINAL ARTICLE

Clinical Comparative Study of Sulbactam/Ampicillin and Imipenem/Cilastatin in Elderly Patients with Community-Acquired Pneumonia

Katsunori Yanagihara, Yuichi Fukuda, Masafumi Seki, Koichi Izumikawa, Yasuhito Higashiyama, Yoshitsugu Miyazaki, Yoichi Hirakata, Kazunori Tomono, Yohei Mizuta, Kazuhiro Tsukamoto, Shigeru Kohno

Author information

Katsunori Yanagihara
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Department of Pharmacotherapeutics, Nagasaki University Graduate School of Pharmaceutical Sciences
Yuichi Fukuda
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Masafumi Seki
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Koichi Izumikawa
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Yasuhito Higashiyama
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Yoshitsugu Miyazaki
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Yoichi Hirakata
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Kazunori Tomono
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Yohei Mizuta
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Kazuhiro Tsukamoto
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Department of Pharmacotherapeutics, Nagasaki University Graduate School of Pharmaceutical Sciences
Shigeru Kohno
Second Department of Internal Medicine, Nagasaki University Graduate School of Pharmaceutical Sciences
Division of Molecular & Clinical Microbiology, Department of Molecular Microbiology & Immunology, Nagasaki University Graduate School of Medical Sciences

Keywords: community-acquired pneumonia, pulmonary infection, clinical trial, elderly patients, antibiotics

JOURNAL OPEN ACCESS

2006 Volume 45 Issue 17 Pages 995-999

DOI https://doi.org/10.2169/internalmedicine.45.1717

Details

Abstract

Objective: To evaluate the clinical usefulness of sulbactam/ampicillin therapy for community-acquired pneumonia in the elderly.
Methodology: A randomized prospective clinical study was conducted in the elderly patients with moderate-to-severe community-acquired bacterial pneumonia.
Results: Overall clinical efficacy of sulbactam/ampicillin therapy (6 g/day) in these patients (efficacy rate: 91.4%) was comparable to that of imipenem/cilastatin therapy (1 g/day; efficacy rate: 87.5%), when each therapy was administered intravenously twice daily for 7-14 days. With regard to clinical efficacy based on disease severity, bacteriological efficacy, improvement of chest X-ray findings and adverse reactions, the two therapies were comparable.
Conclusion: These results suggest that sulbactam/ampicillin therapy has excellent efficacy and tolerability and that it may be highly effective, even in severe cases of pneumonia. This regimen may thus serve as first-line treatment for the treatment of community-acquired pneumonia in elderly patients.

Corresponding author

Register with J-STAGE for free!